Frank Perabo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tachyon Presents Preclinical Data on the Company s Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting

HOUSTON (BUSINESS WIRE) Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Company’s first-in-class KDM4 inhibitor, at the American Association for Cancer Research.

United statesFrank peraboAmerican association for cancer researchErnestn morial convention centerTachyon therapeutics incTachyon therapeuticsAmerican associationCancer researchAnnual meetingConvention centerNew orleansFirst in class inhibitorLysine demethylaseDiffuse largeb cell lymphomaChromatin modifiers

Tachyon Therapeutics, Inc : Tachyon Announces Presentation at the 2021 ESMO Annual Meeting

Tachyon Therapeutics, Inc : Tachyon Announces Presentation at the 2021 ESMO Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Kostenloser wertpapierhandelFrank peraboEuropean society of medical oncologyTachyon therapeutics incCompany or investorTachyon therapeuticsEuropean societyMedical oncologyTriple negative breast cancerProtein phosphataseChief executive officerஐரோப்பிய சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல்ஐரோப்பிய சமூகம்மருத்துவ புற்றுநோயியல்மூன்று எதிர்மறை மார்பக புற்றுநோய்தலைமை நிர்வாகி அதிகாரி